Citations

Clear

7 citation(s) found for "Sun, Kai".

Redefining neurocognitive outcomes after radiation for brain metastases: a patient-level meta-analysis of recovery following initial decline
Cherng, H.R.R. , Sun, Kai , Bentzen, Søren M. , Brown, Paul D. , Armstrong, Terri S. , Gondi, Vinai , Mehta, Minesh P. , Cherng, Hua-Ren R , Palmer, Joshua D , Mehta, Minesh P , Mishra, Mark V , Armstrong, Terri S , Bentzen, Soren M , Sun, Kai , Palmer, Joshua D. , Mishra, Mark V.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 19, 2025 | Volume: 118 | Issue: 2 | Pages: 269-275

10.1093/jnci/djaf264 | PMID 41123288 Get It

Abstract Background Although there are data describing the onset of neurocognitive toxicity following radiation for patients with brain metastases, less is known about the potential for functional cognitive recovery (CR). This study sought to evaluate CR following neurocognitive function failure (NCF) in patients treated with stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and hippocampal avoidance (HA)-WBRT. Methods A pooled analysis of 3 (NCCTG N107C/CEC.3, NCCTG N0574, and NRG CC001) clinical trials was performed. Patients with trial-defined NCF and longitudinal cognitive testing were included. The primary endpoint was time to CR, defined as patients no longer exhibiting a 1 or more standard deviation decline from baseline on any cognitive test. Results A total of 288 patients were included, with a median follow-up of 12.2 months. The cumulative incidence of CR was 38% (95% confidence interval [CI] = 32.5% to 43.9%) at 6 months after NCF. Incidence of CR was significantly improved with post-op SRS vs WBRT (hazard ratio [HR] = 2.68, 95% CI = 1.43 to 5.03, P = .002) and with SRS vs SRS+WBRT (HR = 2.35, 95% CI = 1.16 to 4.79, P = .008). On multivariable analysis, SRS was highly prognostic of CR compared with WBRT (HR = 2.42, 95% CI = 1.70 to 3.45, P < .0001). Meta-analysis demonstrated that conformal RT techniques (SRS or HA-WBRT) conferred a significantly higher rate of CR compared with WBRT (pooled HR = 2.12, 95% CI = 1.49 to 3.02, P < .001); 68% of patients had long-term sustained CR. Conclusions A sizeable proportion of patients who experience NCF following brain radiation eventually attain full and sustained CR, thereby highlighting that neurocognitive decline may not be permanent. The use of conformal radiation techniques results in greater rates of neurocognitive recovery.
Peripheral Iridectomy With Goniosynechialysis and Goniotomy vs Trabeculectomy for Advanced PACG
Lin, Fengbin , Lv, Aiguo , Li, Fei , Song, Yunhe , Xie, Lin , Zhu, Xiaomin , Tang, Li , Zhang, Yao , Huang, Jingjing , Zhang, Hengli , Lŭ, Lan, Xiao, Meichun , Xu, Jiangang , Nie, Xin , Liao, Mengfei, Yang, Yangfan , Gao, Kai , Yuan, Huiping , Song, Wulian , Zuo, Chengguo , Yan, Xiaowei , Wang, Zhenyu , Jin, Ling, Peng, Yu-Ying, Chen, Weirong , Park, Ki Ho , Aung, Tin, Lam, Dennis S.C. , Fan, Sujie , group, TVG study, Liu, Yuhong , Li, Xiaoyan , Zhou, Fengqi, Tang, Guangxian , Nie, Xin, Zuo, Chengguo , Lu, Ping, Zhou, Fengqi , Barton, Keith , Aung, Tin , Weinreb, Robert Neal , Wang, Ning Li , Tham, Clement Chee Yung , Zhang, Xiulan , group, TVG study, Liang, Xiaohong

Mayo Clinic

JAMA Ophthalmology | April 17, 2025 | Volume: 143 | Issue: 6 | Pages: 472

10.1001/jamaophthalmol.2025.0757 | PMID 40244579 Get It

ImportanceThe safety and effectiveness of combining surgical peripheral iridectomy (SPI) with goniosynechialysis (GSL) and goniotomy (GT) vs trabeculectomy for intraocular pressure (IOP) reduction remains unknown.ObjectiveTo investigate the safety and effectiveness at 1 year of SPI + GSL + GT vs trabeculectomy in advanced primary angle-closure glaucoma (PACG) without cataract.Design, Setting, and ParticipantsThis noninferiority randomized clinical trial was conducted at 8 tertiary eye centers in China. A total of 88 Chinese patients (88 eyes) with advanced PACG without cataract were enrolled from January 2022 to July 2023. Data were analyzed from August 2024 to September 2024. Mean (SD) patient age was 60.3 (7.3) years, and 52 patients (59.1%) were female. Forty-three patients were randomized to SPI + GSL + GT and 45 were randomized to trabeculectomy; 86 patients (97.7%) completed the 12-month follow-up.InterventionsParticipants were randomized 1:1 to receive SPI + GSL + GT or trabeculectomy.Main Outcomes and MeasuresThe primary outcome was IOP at 12 months (noninferior margin: 4 mm Hg). Secondary outcomes included surgical success (IOP: 5-18 mm Hg, ≥20% reduction from baseline, with or without antiglaucoma medications); postoperative complications and interventions, including bleb massage, suture lysis, or releasable sutures; and number of antiglaucomatous medications prescribed.ResultsAt 12 months, the SPI + GSL + GT group had a mean (SD) IOP of 15.6 (4.0) mm Hg vs 14.9 (4.2) mm Hg in the trabeculectomy group (difference, 0.5 mm Hg; 95% CI, −1.2 to 2.2; P = .55), which was within the 4-mm Hg noninferiority margin. Qualified success rates were 38 of 43 participants (88.4%) for SPI + GSL + GT and 42 of 45 participants (93.3%) for trabeculectomy (difference, −5.0%; 95% CI, −19.6% to 8.5%; P = .48). However, complete success rates were lower in the SPI + GSL + GT group (26 participants [60.5%]) vs the trabeculectomy group (37 participants [82.2%]; difference, −21.8%; 95% CI, −40.2% to −2.4%; P = .03). Postoperative complications were present for 8 participants (18.6%) in the SPI + GSL + GT group vs 9 participants (20.0%) in the trabeculectomy group (difference, −1.4%; 95% CI, −17.9% to 15.1%; P = .71). Postoperative interventions were lower in the SPI + GSL + GT group (3 participants [7.0%] vs 25 participants [55.6%]; difference, 48.6%; 95% CI, 32.2%-65.0%; P < .001). Median (IQR) numbers of medications used decreased from 2 (0-3) to 0 (0-1) in the SPI + GSL + GT group and from 2 (2-3) to 0 (0-0) in the trabeculectomy group (difference, −0.81; 95% CI, −1.36 to −0.26; P = .004).Conclusions and RelevanceIn this randomized clinical trial among patients with advanced PACG without cataract, SPI + GSL + GT demonstrated noninferiority (4-mm Hg margin) to trabeculectomy for IOP at 12 months, with fewer interventions (including bleb massage, suture lysis, or releasable sutures) but no difference in postoperative medication use. This suggests SPI + GSL + GT as a potential alternative to trabeculectomy for similar cases, pending validation in larger sample sizes with smaller noninferiority margins.Trial RegistrationClinicalTrials.gov Identifier: NCT05163951
Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001
Cherng, H.R.R. , Bentzen, Søren M. , Armstrong, Terri S. , Gondi, Vinai , Brown, Paul D. , Mishra, Mark V. , Cherng, Hua-Ren R , Bentzen, Soren M , Armstrong, Terri S , Mishra, Mark V , Sun, Kai, Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | December 5, 2023 | Volume: 26 | Issue: 5 | Pages: 911-921

10.1093/neuonc/noad226 | PMID 38069666 Get It

Abstract Background Hippocampal avoidant whole brain radiotherapy (HA-WBRT) is the standard of care for patients needing WBRT for brain metastases. This study, using existing data from NRG Oncology CC001 including baseline tumor characteristics and patient-reported MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) scores, sought to identify subgroups of patients that demonstrate differential neuroprotective treatment response to HA-WBRT. Methods An exploratory analysis of NRG CC001, a phase 3 trial in which 518 patients were randomly assigned to WBRT plus memantine or HA-WBRT plus memantine, was performed. Rates of neurocognitive function failure (NCFF) were estimated between subgroups and stratified by arm. Covariate and subgroup interaction with differential treatment response were calculated. Results The benefit of HA-WBRT on decreasing NCFF was seen in patients living ≥ 4 months (HR 0.75, 95% CI: 0.58–0.97, P = .03), whereas patients living < 4 months derived no significant neurocognitive benefit. A significant association between baseline MDASI-BT cognitive factor and treatment response (interaction P = .03) was identified. Patients with lower MDASI-BT scores (less patient-reported cognitive impairment) derived significantly greater benefit (HR = 0.64, 95% CI: 0.48–0.85, P = .002) compared to those with highest MDASI-BT scores (HR = 1.24, 95% CI: 0.76–2.04, P = .39). Tumor histology also had a significant interaction (P = .01) with treatment response. Primary lung histology patients derived cognitive failure risk reduction (HR = 0.58, 95% CI: 0.43–0.77, P = .0007) from HA-WBRT, in contrast to nonlung primary histology patients (HR = 1.15, 95% CI: 0.78–1.50, P = .48). Conclusions Differential neuroprotective response to HA-WBRT was identified in this analysis. Patients surviving ≥ 4 months derived benefit from HA-WBRT. There is evidence of heterogeneity of treatment effect for patients with less severe patient-reported cognitive impairment at baseline and those with primary lung histology.
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials
Iwatsubo, Takeshi , Iwata, Atsushi , Suzuki, Kazushi , Ihara, Ryoko , Arai, Hiroyuki , Ishii, Kenji , Senda, Michio , Kuwano, Ryozo, Initiative, Japanese Alzheimer's Disease Neuroimaging, Sun, Chung‐Kai , Petersen, Ronald C. , Weiner, Michael W. , Aisen, Paul , Donohue, Michael , Initiative, Alzheimer's Disease Neuroimaging, Shoji, Mikio , Ito, Kengo , Ikeuchi, Takeshi , Matsuda, Hiroshi , Initiative, Japanese Alzheimer's Disease Neuroimaging, Beckett, Laurel , Initiative, Alzheimer's Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

Alzheimer's & Dementia | May 9, 2018 | Volume: 14 | Issue: 8 | Pages: 1077-1087

10.1016/j.jalz.2018.03.009 | PMID 29753531 Get It

AbstractIntroductionWe conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America.MethodsA total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography‐ or cerebrospinal fluid amyloid β(1–42)‐positive LMCI and mild AD between J‐ADNI and ADNI.ResultsAmyloid positivity rates were significantly higher in normal cognition of ADNI but at similar levels in LMCI and mild AD between J‐ADNI and ADNI. Profiles of decline in cognitive or functional measures in amyloid‐positive LMCI in J‐ADNI (n = 75) and ADNI (n = 269) were remarkably similar, whereas those in mild AD were milder in J‐ADNI (n = 73) compared with ADNI (n = 230).DiscussionThese results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
Donohue, Michael , Petersen, Ronald C. , Sun, Chung‐Kai , Weiner, Michael W. , Aisen, Paul , Initiative, for the Alzheimer’s Disease Neuroimaging, Sperling, Reisa Anne , Initiative, for the Alzheimer’s Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

JAMA | June 13, 2017 | Volume: 317 | Issue: 22 | Pages: 2305

10.1001/jama.2017.6669 | PMID 28609533 Get It

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials
Moghadam, Setareh H., Roe, Allyson D., Sun, Chung‐Kai , Edland, Steven D. , Thomas, Ronald G. , Petersen, Ronald C. , Sano, Mary , Aisen, Paul, Donohue, Michael , Galasko, Douglas , Rissman, Robert A.

Mayo Clinic

Alzheimer's & Dementia | October 8, 2014 | Volume: 11 | Issue: 9 | Pages: 1069-1079

10.1016/j.jalz.2014.07.156 | PMID 25301682 Get It

IntroductionLittle is known about the utility of plasma amyloid beta (Aβ) in clinical trials of Alzheimer's disease (AD).MethodsWe analyzed longitudinal plasma samples from two large multicenter clinical trials: (1) donezepil and vitamin E in mild cognitive impairment (n = 405, 24 months) and (2) simvastatin in mild to moderate AD (n = 225, 18 months).ResultsBaseline plasma Aβ was not related to cognitive or clinical progression. We observed a decrease in plasma Aβ40 and 42 among apolipoprotein E epsilon 4 (APOE ε4) carriers relative to noncarriers in the mild cognitive impairment trial. Patients treated with simvastatin showed a significant increase in Aβ compared with placebo. We found significant storage time effects and considerable plate‐to‐plate variation.DiscussionWe found no support for the utility of plasma Aβ as a prognostic factor or correlate of cognitive change. Analysis of stored specimens requires careful standardization and experimental design, but plasma Aβ may prove useful in pharmacodynamic studies of antiamyloid drugs.